Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989593 · ClinicalTrials.gov registry record · NA
Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions
A NA study of Hypospadias and DSD, sponsored by Sarah Schlegel.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06989593: Recruiting NA study of Hypospadias and DSD, sponsored by Sarah Schlegel.
NCT06989593 is a NA study of Hypospadias and DSD that is actively recruiting participants, run by Sarah Schlegel. The registered enrollment target is 20 participants, below the 146-participant average among 3 other Hypospadias trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06989593, a NA study of Hypospadias and DSD, is actively recruiting participants, sponsored by Sarah Schlegel.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether a journaling intervention can reduce stress and anxiety in parents of children with urogenital conditions (such as differences of sex development and hypospadias). The main questions it aims to answer are: * Does guided journaling help to reduce anxiety levels in parents of children with urogenital conditions? * What are parents' perspectives on group-based writing interventions for future support programs? Participants will: * Complete a short anxiety questionnaire (the General Anxiety Disorder-7 scale) at the beginning of the study * Receive a physical journal with 5 writing prompts designed to help process emotions related to their child's condition * Complete 5 journal entries over several weeks, writing about their experiences and feelings * Complete the same anxiety questionnaire again after finishing the journal entries * Participate in a 45-minute interview to discuss how the journaling affected their stress levels and gather feedback on potential group-based writing programs
Primary Outcome
Change from baseline in General Anxiety Disorder-7 (GAD-7) scores. The GAD-7 is a validated 7-item self-report questionnaire used to assess anxiety symptom severity. Scores range from 0-21, with higher scores indicating greater anxiety symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Narrative Medicine Journaling Intervention
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06989593 shows while recruiting
NCT06989593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 146-participant average among 3 other Hypospadias trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Hypospadias appearing as the primary indexed condition, and to 1 intervention - of which Narrative Medicine Journaling Intervention is the first listed.
NCT06989593 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06989593 about?
NCT06989593 is a clinical study titled "Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions". The goal of this clinical trial is to learn whether a journaling intervention can reduce stress and anxiety in parents of children with urogenital conditions (such as differences of sex development and hypospadias). The main questions it aims to answer are: * Does guided journaling help to reduce ...
What is the current status of trial NCT06989593?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-10-10. Estimated completion is 2026-05.
What conditions does trial NCT06989593 study?
This clinical trial studies the following conditions: Hypospadias, DSD.
What interventions are being tested in trial NCT06989593?
The interventions under investigation include: Narrative Medicine Journaling Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06989593?
This trial is sponsored by Sarah Schlegel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989593 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypospadias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI